Literature DB >> 27111041

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.

C Koenecke1, D Heim2, A van Biezen3, M Heuser1, M Aljurf4, S Kyrcz-Krzemien5, L Volin6, C A de Souza7, T Gedde-Dahl8, H Sengeloev9, U Schanz10, M Komarnicki11, C H Arroyo12, E Tholouli13, E Gluckman14, A Esquirol15, I Yakoub-Agha16, G Gürman17, E Olavarria18, N Kröger19.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27111041     DOI： 10.1038/bmt.2016.97

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Authors:  A John Barrett; Sawa Ito
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

3.  Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Authors:  Jirí Pavlu; Richard M Szydlo; John M Goldman; Jane F Apperley
Journal:  Blood       Date:  2010-10-21       Impact factor: 22.113

4.  Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation.

Authors:  R A Clift; C D Buckner; E D Thomas; K Doney; A Fefer; P E Neiman; J Singer; J Sanders; P Stewart; K M Sullivan; J Deeg; R Storb
Journal:  Lancet       Date:  1982-09-18       Impact factor: 79.321

5.  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Authors:  Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

6.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

7.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  Alois Gratwohl; Ronald Brand; Jane Apperley; Charles Crawley; Tapani Ruutu; Paolo Corradini; Enric Carreras; Agnes Devergie; Cesare Guglielmi; Hans-Jochen Kolb; Dietger Niederwieser
Journal:  Haematologica       Date:  2006-03-01       Impact factor: 9.941

Review 8.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.